Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lefkovits, J.
  • Topol, Eric

publication date

  • September 1997

journal

  • Progress in Cardiovascular Diseases  Journal

abstract

  • A large number of drug trials for prevention of restenosis have been conducted with many showing little or conflicting benefit. Antiplatelets such as aspirin, ticlopidine and thromboxane A2 receptor inhibitors have not shown a clear benefit. Similarly, antithrombotics, either acting indirectly such as heparin, or as direct thrombin inhibitors such as hirudin and hirulog, do not prevent restenosis. Trials with ACE inhibitors, HMG-CoA reductase inhibitors and fish-oil supplements have yielded inconclusive results. The antiproliferatives, angiopeptin, trapidil and tranilast have shown some benefit in small-scale studies. Other drug classes of potential benefit include the glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers and nitric oxide donors. Drug research into restenosis prevention has been hampered by problems with the definition of restenosis and the applicability in humans of animal models. Although no single drug has conclusively proven effective yet, the promise of a number of agents, together with other nonpharmacological strategies will likely result in further reductions in the incidence of restenosis.

subject areas

  • Angioplasty, Balloon, Coronary
  • Angiotensin-Converting Enzyme Inhibitors
  • Animals
  • Antibodies, Monoclonal
  • Anticoagulants
  • Cardiovascular Agents
  • Constriction, Pathologic
  • Coronary Angiography
  • Coronary Disease
  • Coronary Vessels
  • Disease Models, Animal
  • Humans
  • Hypolipidemic Agents
  • Immunoglobulin Fab Fragments
  • Oligopeptides
  • Platelet Aggregation Inhibitors
  • Platelet Membrane Glycoproteins
  • Recurrence
  • Somatostatin
  • Trapidil
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0033-0620

Digital Object Identifier (DOI)

  • 10.1016/s0033-0620(97)80006-0

PubMed ID

  • 9327830
scroll to property group menus

Additional Document Info

start page

  • 141

end page

  • 158

volume

  • 40

issue

  • 2

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support